Evaluating outcomes of surgery in early-stage lung cancer patients
Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the Surgery: A Retrospective Multi-center Study (EarlyLC-RW)
This study is testing how well different types of surgery work for people with early-stage lung cancer to help improve treatment decisions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20000 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06483698 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the long-term clinical outcomes and efficacy of surgical interventions in patients with early-stage lung cancer using real-world data. It focuses on determining the optimal surgical strategies and identifying risk factors associated with early-stage lung cancer. Participants will undergo surgical procedures such as sublobar resection or lobectomy, and their outcomes will be analyzed to provide insights that could enhance clinical decision-making and patient management. The study seeks to gather comprehensive data from patients aged 18 to 85 who meet specific eligibility criteria.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 85 with stage I lung cancer who have not received prior chemotherapy or radiation therapy.
Not a fit: Patients who have previously undergone chemotherapy, radiotherapy, or other anti-tumor therapies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved surgical strategies and better management of early-stage lung cancer, ultimately enhancing patient outcomes.
How similar studies have performed: Other studies have shown success in evaluating surgical outcomes in lung cancer, but this specific approach utilizing real-world data is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged between 18 and 85; 2. Did not receive neoadjuvant therapy before surgery; 3. No history of radiation therapy; 4. Eastern Cooperative Oncology Group (ECOG) score is 0-1; 5. Have complete clinically relevant information including imaging data; 6. All patients underwent relevant preoperative examinations; 7. Stage I lung cancer (International Association for the Study of Lung Cancer/The Union for International Cancer Control staging eighth edition); Exclusion Criteria: 1. Have previously received chemotherapy, radiotherapy and other anti-tumor therapy; 2. Data loss and error in medical records due to human/objective reasons.
Where this trial is running
Beijing, Beijing Municipality
- Shugeng Gao — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Shugeng Gao, MD — Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Study coordinator: Shugeng Gao, MD
- Email: gaoshugeng@cicams.ac.cn
- Phone: 8610-87788177
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.